Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Zahra Bakhtiary, Jaleh Barar, Ayuob Aghanejad, Amir Ata Saei, Elhameh Nemati, Jafar Ezzati Nazhad Dolatabadi & Yadollah Omidi. (2017) Microparticles containing erlotinib-loaded solid lipid nanoparticles for treatment of non-small cell lung cancer. Drug Development and Industrial Pharmacy 43:8, pages 1244-1253.
Read now
Read now
Articles from other publishers (32)
Wafa K. Fatani, Fadilah S. Aleanizy, Fulwah Y. Alqahtani, Mohammed M. Alanazi, Abdullah A. Aldossari, Faiyaz Shakeel, Nazrul Haq, Hosam Abdelhady, Hamad M. Alkahtani & Ibrahim A. Alsarra. (2023) Erlotinib-Loaded Dendrimer Nanocomposites as a Targeted Lung Cancer Chemotherapy. Molecules 28:9, pages 3974.
Crossref
Crossref
Ksenia Myacheva, Andrew Walsh, Marisa Riester, Giulia Pelos, Jane Carl & Sven Diederichs. (2023) CRISPRi screening identifies CASP8AP2 as an essential viability factor in lung cancer controlling tumor cell death via the AP-1 pathway. Cancer Letters 552, pages 215958.
Crossref
Crossref
Anandu Kizhakkedath Ratheesh, Ajay Pottankottu Jayan, Aneesh Thankappan Presanna & Saiprabha Vijayakumar Nirmala. (2022) Pyrimidine derivatives as EGFR tyrosine kinase inhibitors in non‐small‐cell lung cancer: A comprehensive review. Chemical Biology & Drug Design 100:4, pages 599-621.
Crossref
Crossref
Kexin Huang, Lifeng Yang, Yubo Wang, Liyu Huang, Xiaobo Zhou & Wei Zhang. (2022) Identification of non-small-cell lung cancer subtypes by unsupervised clustering of CT image features with distinct prognoses and gene pathway activities. Biomedical Signal Processing and Control 76, pages 103643.
Crossref
Crossref
Chaitali Taiwade, Aditi Fulfager, Hardik Bhargave, Govind Soni & Khushwant Yadav. (2021) Erlotinib Hydrochloride Novel Drug Delivery Systems: A Mini Review Unravelling the Role of Micro- and Nanocarriers. Drug Delivery Letters 11:4, pages 295-306.
Crossref
Crossref
Jiawei Dai, Minlin Jiang, Kan He, Hao Wang, Peixin Chen, Haoyue Guo, Wencheng Zhao, Hui Lu, Yayi He & Caicun Zhou. (2021) DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and Promote Poor Prognosis of Advanced Lung Cancer. Frontiers in Oncology 11.
Crossref
Crossref
Yayi He, Lele Song, Hao Wang, Peixin Chen, Yu Liu, Hui Sun, Xiaobin Li, Shiying Dang, Guifeng Liu, Xinyi Liu, Shifu Chen, Xiaoni Zhang, Paul Hofman, Junji Uchino, Henry S. Park, Jose M. Pacheco, Fabrizio Tabbò, Mingyan Xu, Jiawei Dai, Kan He, Yang Yang & Caicun Zhou. (2020) Mutational Profile Evaluates Response and Survival to First‐Line Chemotherapy in Lung Cancer. Advanced Science 8:4, pages 2003263.
Crossref
Crossref
Ayushi Rai, Saba Noor, Syed Ishraque Ahmad, Mohamed F. Alajmi, Afzal Hussain, Hashim Abbas & Gulam Mustafa Hasan. (2021) Recent Advances and Implication of Bioengineered Nanomaterials in Cancer Theranostics. Medicina 57:2, pages 91.
Crossref
Crossref
Ana Oaknin, Claire F. Friedman, Lynda D. Roman, Anishka D'Souza, Irene Brana, François-Clement Bidard, Jonathan Goldman, Edwin A. Alvarez, Valentina Boni, Adam C. ElNaggar, Rodolfo Passalacqua, Khanh T.M. Do, Alessandro D. Santin, Kiana Keyvanjah, Feng Xu, Lisa D. Eli, Alshad S. Lalani, Richard P. Bryce, David M. Hyman, Funda Meric-Bernstam, David B. Solit & Bradley J. Monk. (2020) Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial. Gynecologic Oncology 159:1, pages 150-156.
Crossref
Crossref
Pei Cheng Jin, Bo Gou & Wei Qian. (2019) Urinary markers in treatment monitoring of lung cancer patients with bone metastasis. The International Journal of Biological Markers 34:3, pages 243-250.
Crossref
Crossref
Alessandro Inno, Vincenzo Di Noia, Maurizio Martini, Ettore D’Argento, Mariantonietta Di Salvatore, Vincenzo Arena, Giovanni Schinzari, Armando Orlandi, Luigi Maria Larocca, Alessandra Cassano & Carlo Barone. (2018) Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis. Pathology & Oncology Research.
Crossref
Crossref
Motonobu Saito, Hiroyuki Suzuki, Koji Kono, Seiichi Takenoshita & Takashi Kohno. (2017) Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy. Surgery Today 48:1, pages 1-8.
Crossref
Crossref
Francois Ng Kee Kwong, Andrew G. Nicholson, Celeste L. Harrison, Philip M. Hansbro, Ian M. Adcock & Kian Fan Chung. (2017) Is mitochondrial dysfunction a driving mechanism linking COPD to nonsmall cell lung carcinoma?. European Respiratory Review 26:146, pages 170040.
Crossref
Crossref
Yoshiaki Inoue, Jun Shiihara, Hitoshi Miyazawa, Hiromitsu Ohta, Megumi Higo, Yoshiaki Nagai, Kunihiko Kobayashi, Yasuo Saijo, Masanori Tsuchida, Mitsuo Nakayama & Koichi Hagiwara. (2017) A highly specific and sensitive massive parallel sequencer-based test for somatic mutations in non-small cell lung cancer. PLOS ONE 12:4, pages e0176525.
Crossref
Crossref
Yuanxin Tian, Yonghuan Yu, Yudong Shen, Hua Wan, Shan Chang, Tingting Zhang, Shanhe Wan & Jiajie Zhang. (2017) Molecular Simulation Studies on the Binding Selectivity of Type-I Inhibitors in the Complexes with ROS1 versus ALK. Journal of Chemical Information and Modeling 57:4, pages 977-987.
Crossref
Crossref
T Puri. (2017) Targeted therapy in nonsmall cell lung cancer. Indian Journal of Cancer 54:1, pages 83.
Crossref
Crossref
Yan Chen, Wandan Huang, Feiyu Chen, Guoping Hu, Fenglei Li, Jianhua Li & Aiguo Xuan. (2016) Pregnane X receptors regulate CYP2C8 and P-glycoprotein to impact on the resistance of NSCLC cells to Taxol. Cancer Medicine 5:12, pages 3564-3571.
Crossref
Crossref
Verena Schildgen, Jessica Lüsebrink, Oliver Schildgen, Erich Stoelben & Michael Brockmann. (2016) Epidemiology of driver mutations in lung cancer in a German tertiary hospital in patients with testing indication. Personalized Medicine 13:4, pages 315-323.
Crossref
Crossref
Marcin Nicoś, Paweł Krawczyk, Bożena Jarosz, Marek Sawicki, Justyna Szumiłło, Tomasz Trojanowski & Janusz Milanowski. (2015) Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer. Clinical and Experimental Medicine 16:2, pages 169-176.
Crossref
Crossref
Chi-Chen Lin, Jing-Ting Chen, Meng-Wei Lin, Chia-Hao Chan, Yueh-Feng Wen, Shin-Bei Wu, Ting-Wen Chung, Kevin W. Lyu, Hsiu-Chuan Chou & Hong-Lin Chan. (2015) Identification of protein expression alterations in gefitinib-resistant human lung adenocarcinoma: PCNT and mPR play key roles in the development of gefitinib-associated resistance. Toxicology and Applied Pharmacology 288:3, pages 359-373.
Crossref
Crossref
Christopher T. Cummings, Weihe Zhang, Kurtis D. Davies, Gregory D. Kirkpatrick, Dehui Zhang, Deborah DeRyckere, Xiaodong Wang, Stephen V. Frye, H. Shelton Earp & Douglas K. Graham. (2015) Small Molecule Inhibition of MERTK Is Efficacious in Non–Small Cell Lung Cancer Models Independent of Driver Oncogene Status. Molecular Cancer Therapeutics 14:9, pages 2014-2022.
Crossref
Crossref
Florian Laenger, Nicolas Dickgreber & Ulrich Lehmann. 2015. Lung Cancer. Lung Cancer
95
118
.
Minsoo Song. (2015) Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer. Journal of Medicinal Chemistry 58:9, pages 3672-3681.
Crossref
Crossref
Shanthi Kanthala, Sandeep Pallerla & Seetharama Jois. (2015) Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptors. Future Oncology 11:5, pages 865-878.
Crossref
Crossref
Xuelin Men, Lingcheng Wang, Wenfei Yu & Yuanrong Ju. (2015) Cullin7 Is Required for Lung Cancer Cell Proliferation and Is Overexpressed in Lung Cancer. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 22:2, pages 123-128.
Crossref
Crossref
Philipp Jurmeister, Dido Lenze, Erika Berg, Stefanie Mende, Frank Schäper, Udo Kellner, Hermann Herbst, Christine Sers, Jan Budczies, Manfred Dietel, Michael Hummel & Maximilian von Laffert. (2015) Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing. Lung Cancer 87:2, pages 122-129.
Crossref
Crossref
Elena Ardini, Roberta Bosotti, Andrea Lombardi Borgia, Cristina De Ponti, Alessio Somaschini, Rosaria Cammarota, Nadia Amboldi, Laura Raddrizzani, Andrea Milani, Paola Magnaghi, Dario Ballinari, Daniele Casero, Fabio Gasparri, Patrizia Banfi, Nilla Avanzi, Maria B. Saccardo, Rachele Alzani, Tiziano Bandiera, Eduard Felder, Daniele Donati, Enrico Pesenti, Andrea Sartore-Bianchi, Marcello Gambacorta, Marco A. Pierotti, Salvatore Siena, Silvio Veronese, Arturo Galvani & Antonella Isacchi. (2014) The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Molecular Oncology 8:8, pages 1495-1507.
Crossref
Crossref
Johan F Vansteenkiste. (2014) Ceritinib for treatment of ALK-rearranged advanced non-small-cell lung cancer. Future Oncology 10:12, pages 1925-1939.
Crossref
Crossref
Robert L. Cohen & Jeff Settleman. (2014) From Cancer Genomics to Precision Oncology—Tissue’s Still an Issue. Cell 157:7, pages 1509-1514.
Crossref
Crossref
Bilal Piperdi, Amartej Merla & Roman Perez-Soler. (2014) Targeting Angiogenesis in Squamous Non-Small Cell Lung Cancer. Drugs 74:4, pages 403-413.
Crossref
Crossref
Benedikte Jacobsen. (2014) C4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinoma. World Journal of Clinical Oncology 5:4, pages 621.
Crossref
Crossref
Marius Ilie, ?lodie Long, V?ronique Hofman, Virginie Lespinet, Olivier Bordone, Kevin Washetine, Virginie Gavric-Tanga & Paul Hofman. (2014) Les m?thodes de s?quen?age de ? nouvelle g?n?ration ? (NGS) et le cancer broncho-pulmonaire: principales technologies, applications et limites actuelles en pathologie. Revue Francophone des Laboratoires 2014:458, pages 51-58.
Crossref
Crossref